CLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Outperform (2) to Hold (3) with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE